JP2015511962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511962A5 JP2015511962A5 JP2015500534A JP2015500534A JP2015511962A5 JP 2015511962 A5 JP2015511962 A5 JP 2015511962A5 JP 2015500534 A JP2015500534 A JP 2015500534A JP 2015500534 A JP2015500534 A JP 2015500534A JP 2015511962 A5 JP2015511962 A5 JP 2015511962A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding molecule
- binding
- multispecific antigen
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000012636 effector Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 3
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 3
- 102000025171 antigen binding proteins Human genes 0.000 claims description 3
- 108091000831 antigen binding proteins Proteins 0.000 claims description 3
- 102100025222 CD63 antigen Human genes 0.000 claims description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 2
- 101100346152 Drosophila melanogaster modSP gene Proteins 0.000 claims description 2
- 102100040890 Glucagon receptor Human genes 0.000 claims description 2
- 102000012153 HLA-B27 Antigen Human genes 0.000 claims description 2
- 108010061486 HLA-B27 Antigen Proteins 0.000 claims description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 2
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims description 2
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims description 2
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims description 2
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims description 2
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims description 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 101150013552 LDLR gene Proteins 0.000 claims description 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims description 2
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims description 2
- 102100029000 Prolactin receptor Human genes 0.000 claims description 2
- 102100034201 Sclerostin Human genes 0.000 claims description 2
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 108010065059 methylaspartate ammonia-lyase Proteins 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 108091005703 transmembrane proteins Proteins 0.000 claims description 2
- 102000035160 transmembrane proteins Human genes 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- -1 MHC-I Proteins 0.000 claims 1
- 101150002688 kremen1 gene Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019016596A JP7308041B2 (ja) | 2012-03-14 | 2019-02-01 | 多重特異性抗原結合分子およびその使用 |
| JP2022008369A JP7579291B2 (ja) | 2012-03-14 | 2022-01-24 | 多重特異性抗原結合分子およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610494P | 2012-03-14 | 2012-03-14 | |
| US61/610,494 | 2012-03-14 | ||
| US201261721831P | 2012-11-02 | 2012-11-02 | |
| US61/721,831 | 2012-11-02 | ||
| US201361751286P | 2013-01-11 | 2013-01-11 | |
| US61/751,286 | 2013-01-11 | ||
| PCT/US2013/030636 WO2013138400A1 (en) | 2012-03-14 | 2013-03-13 | Multispecific antigen-binding molecules and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018071539A Division JP2018168152A (ja) | 2012-03-14 | 2018-04-03 | 多重特異性抗原結合分子およびその使用 |
| JP2019016596A Division JP7308041B2 (ja) | 2012-03-14 | 2019-02-01 | 多重特異性抗原結合分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511962A JP2015511962A (ja) | 2015-04-23 |
| JP2015511962A5 true JP2015511962A5 (cg-RX-API-DMAC7.html) | 2016-05-12 |
| JP6883944B2 JP6883944B2 (ja) | 2021-06-09 |
Family
ID=48014317
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500534A Active JP6883944B2 (ja) | 2012-03-14 | 2013-03-13 | 多重特異性抗原結合分子およびその使用 |
| JP2018071539A Withdrawn JP2018168152A (ja) | 2012-03-14 | 2018-04-03 | 多重特異性抗原結合分子およびその使用 |
| JP2019016596A Active JP7308041B2 (ja) | 2012-03-14 | 2019-02-01 | 多重特異性抗原結合分子およびその使用 |
| JP2022008369A Active JP7579291B2 (ja) | 2012-03-14 | 2022-01-24 | 多重特異性抗原結合分子およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018071539A Withdrawn JP2018168152A (ja) | 2012-03-14 | 2018-04-03 | 多重特異性抗原結合分子およびその使用 |
| JP2019016596A Active JP7308041B2 (ja) | 2012-03-14 | 2019-02-01 | 多重特異性抗原結合分子およびその使用 |
| JP2022008369A Active JP7579291B2 (ja) | 2012-03-14 | 2022-01-24 | 多重特異性抗原結合分子およびその使用 |
Country Status (19)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110111406A1 (en) | 2008-04-11 | 2011-05-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| CN104302664B (zh) * | 2012-03-14 | 2021-11-26 | 瑞泽恩制药公司 | 多特异性抗原结合分子及其用途 |
| ES2749200T3 (es) | 2012-05-10 | 2020-03-19 | Bioatla Llc | Anticuerpos monoclonales multiespecíficos |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10072076B2 (en) | 2013-03-14 | 2018-09-11 | Regeneron Pharmaceuticals, Inc. | Human antibodies to NAv1.7 |
| EA201691027A1 (ru) | 2013-11-20 | 2016-12-30 | Ридженерон Фармасьютикалз, Инк. | Модуляторы aplnr и их применение |
| EP3107565A4 (en) * | 2014-02-21 | 2017-08-23 | Regeneron Pharmaceuticals, Inc. | Methods, compositions and kits for cell specific modulation of target antigens |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| KR102851747B1 (ko) * | 2015-12-08 | 2025-08-28 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
| US20190352423A1 (en) * | 2016-02-05 | 2019-11-21 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| RU2018139811A (ru) * | 2016-04-15 | 2020-05-15 | Займворкс Инк. | Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства |
| EP3448891A1 (en) * | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| KR20190074310A (ko) | 2016-11-08 | 2019-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| WO2018107109A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| WO2018139623A1 (en) * | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| MY205898A (en) | 2017-02-17 | 2024-11-19 | Denali Therapeutics Inc | Engineered transferrin receptor binding polypeptides |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| JP7348844B2 (ja) * | 2017-06-07 | 2023-09-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 内部移行酵素のための組成物および方法 |
| SG11201911886PA (en) | 2017-06-27 | 2020-01-30 | Regeneron Pharma | Non-human animals comprising a humanized asgr1 locus |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| WO2019094395A2 (en) | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| AU2019205542B2 (en) | 2018-01-08 | 2025-10-23 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| SG11202007363TA (en) | 2018-02-07 | 2020-08-28 | Regeneron Pharma | Methods and compositions for therapeutic protein delivery |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| AU2019262953B2 (en) | 2018-04-30 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof |
| SG11202010909RA (en) | 2018-05-09 | 2020-12-30 | Regeneron Pharma | Anti-msr1 antibodies and methods of use thereof |
| US12252544B2 (en) * | 2018-05-17 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Anti-CD63 antibodies, conjugates, and uses thereof |
| MX2020013606A (es) | 2018-06-14 | 2021-05-27 | Bioatla Inc | Constructos de anticuerpos multiespecificos. |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN113301925A (zh) * | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
| TWI873112B (zh) | 2018-12-28 | 2025-02-21 | 日商協和麒麟股份有限公司 | 與TfR結合之雙專一性抗體 |
| JP2022521751A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CN113677705A (zh) * | 2019-03-04 | 2021-11-19 | 南通壹宸生物医药科技有限公司 | 新型双特异性结合分子及其药物偶联物 |
| WO2020247827A1 (en) * | 2019-06-06 | 2020-12-10 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| WO2021022039A1 (en) * | 2019-07-30 | 2021-02-04 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| GB2612450A (en) | 2020-04-24 | 2023-05-03 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP2023539645A (ja) | 2020-08-26 | 2023-09-15 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｎｋｐ３０に結合する抗体分子およびその使用 |
| HUE069371T2 (hu) | 2021-02-03 | 2025-02-28 | Mythic Therapeutics Inc | MET elleni ellenanyagok és alkalmazásaik |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| CA3226269A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| CA3242731A1 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease |
| CA3257739A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS CONTAINING A MODIFIED TRANSFERRIN RECEPTOR LOCUS |
| TW202513801A (zh) | 2023-07-28 | 2025-04-01 | 美商雷傑納榮製藥公司 | 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入 |
| WO2025029654A2 (en) | 2023-07-28 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US5229272A (en) | 1989-04-25 | 1993-07-20 | Igen, Inc. | Catalytic antibody components |
| US5156965A (en) | 1983-11-29 | 1992-10-20 | Igen, Inc. | Catalytic antibodies |
| US5126258A (en) | 1984-09-07 | 1992-06-30 | Scripps Clinic And Research Foundation | Molecules with antibody combining sites that exhibit catalytic properties |
| US5030717A (en) | 1986-09-17 | 1991-07-09 | Scripps Clinic And Research Foundation | Antibodies which catalyze hydrolysis of ester bonds |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5851527A (en) | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
| US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5858728A (en) | 1991-03-13 | 1999-01-12 | Common Services Agency | Monoclonal antibody against LPS core |
| US5436153A (en) | 1992-12-02 | 1995-07-25 | Sprecher; Cindy A. | Human amyloid protein precursor homolog and Kunitz-type inhibitor |
| EP0696318A4 (en) | 1993-04-23 | 1998-04-15 | Igen Inc | CATALYTIC ANTIBODIES HYDROLYSING PRIMARY AMIDES AND METHODS FOR OBTAINING SUCH ANTIBODIES |
| US5602021A (en) | 1994-12-29 | 1997-02-11 | Catalytic Antibodies, Inc. | Method for generating proteolytic enzymes specific against a selected peptide sequence |
| ES2191827T3 (es) | 1996-10-17 | 2003-09-16 | Immunomedics Inc | Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular. |
| CN1259875A (zh) | 1997-06-11 | 2000-07-12 | 伦敦大学药学院 | 含有与前体药物结合的抗体－酶偶联物的药物组合物 |
| IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
| ATE424415T1 (de) | 1998-01-15 | 2009-03-15 | Ct Molecular Med & Immunology | BISPEZIFISCHE ßTARGETING MOIETYß UMFASSEND EINEN ANTIKÖRPER GEGEN CEA (CARCINOEMBRYONIC ANTIGEN) UND DIE LIGANDEN-BINDENDE REGION DER IL13REZEPTOR ALPHA UNTEREINHEIT |
| US6703488B1 (en) * | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| US6855804B2 (en) | 1998-03-23 | 2005-02-15 | Board Of Regents, The University Of Texas System | Covalently reactive transition state analogs and methods of use thereof |
| US6235714B1 (en) | 1998-03-23 | 2001-05-22 | Sudhir Paul | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7223556B1 (en) | 1998-10-09 | 2007-05-29 | President And Fellows Of Harvard College | Targeted proteolysis by recruitment to ubiquitin protein ligases |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2001009186A2 (en) * | 1999-07-30 | 2001-02-08 | Medarex, Inc. | Therapeutic compounds comprised of anti-fc receptor binding agents |
| EP1231944A2 (en) | 1999-11-15 | 2002-08-21 | University Of Southern California | Targeted delivery of therapeutic and diagnostic moieties |
| DE10034607A1 (de) | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| AU2001295041A1 (en) | 2000-09-08 | 2002-03-22 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20060210474A1 (en) | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7534429B2 (en) | 2000-11-29 | 2009-05-19 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7431923B2 (en) | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7442777B2 (en) | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1439857B1 (en) | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
| EP1633865B1 (en) | 2003-06-18 | 2011-09-28 | Bayer Pharma Aktiengesellschaft | New biological entities and the use thereof |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| TWI356064B (en) * | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| US7371539B2 (en) | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| NZ552745A (en) | 2004-07-16 | 2009-01-31 | Micromet Ag | Expression-enhanced polypeptides |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US20080089891A1 (en) | 2006-07-26 | 2008-04-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US9127293B2 (en) | 2006-07-26 | 2015-09-08 | The University Of Chicago | Receptor-mediated delivery: compositions and methods |
| CN101522717A (zh) | 2006-08-04 | 2009-09-02 | 阿斯利康(瑞典)有限公司 | 针对ErbB2的人抗体 |
| WO2008051326A2 (en) * | 2006-08-21 | 2008-05-02 | President And Fellows Of Harvard College | Identification of contactins and l1- cams as ligands for the amyloid precursor protein |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| AU2008282218A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| WO2009094561A1 (en) * | 2008-01-24 | 2009-07-30 | The Government Of The United States Of America As Represented By The Secretary Of The Departmentof | Induced internalization of surface receptors |
| WO2009120922A2 (en) * | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| KR20110047255A (ko) * | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체 |
| JP5587975B2 (ja) | 2009-04-07 | 2014-09-10 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体 |
| EP2241576A1 (en) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
| WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
| EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| US20110275065A1 (en) * | 2010-05-07 | 2011-11-10 | Ranju Ralhan | Methods and compositions for the diagnosis and treatment of thyroid cancer |
| CN107253992B (zh) * | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| JP6177231B2 (ja) | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Ｈｅｒ２に対する二重特異性抗体 |
| US20120282176A1 (en) | 2011-04-20 | 2012-11-08 | Roche Glycart Ag | Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier |
| WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN104302664B (zh) * | 2012-03-14 | 2021-11-26 | 瑞泽恩制药公司 | 多特异性抗原结合分子及其用途 |
| AU2013258844B2 (en) | 2012-05-10 | 2017-12-21 | Zymeworks Bc Inc. | Single-arm monovalent antibody constructs and uses thereof |
| MY178542A (en) | 2012-08-29 | 2020-10-15 | Hoffmann La Roche | Blood brain barrier shuttle |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US20160002342A1 (en) | 2013-03-15 | 2016-01-07 | Xinghang Ma | Anti-prolactin receptor antibody formulations |
| EP2994164B1 (en) | 2013-05-08 | 2020-08-05 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| WO2014185908A2 (en) | 2013-05-15 | 2014-11-20 | The Translational Genomics Research Institute | Hybridoma clones, monoclonal antibodies, and methods of use |
| US9388243B2 (en) | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| HK1231367A1 (zh) | 2014-06-02 | 2017-12-22 | Regeneron Pharmaceuticals, Inc. | 抗体药物偶联物、试剂和制备方法及其治疗用途 |
| NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| KR102851747B1 (ko) | 2015-12-08 | 2025-08-28 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
| US20190352423A1 (en) | 2016-02-05 | 2019-11-21 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| IL266917B2 (en) | 2016-11-29 | 2023-10-01 | Regeneron Pharma | Anti-human prolactin receptor (prlr) antibody-drug conjugates and use thereof in combination therapy of prlr positive breast cancer |
| JP7348844B2 (ja) | 2017-06-07 | 2023-09-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 内部移行酵素のための組成物および方法 |
| PE20200481A1 (es) | 2017-07-10 | 2020-03-03 | Bayer Pharma AG | Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos |
| AU2019262953B2 (en) | 2018-04-30 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof |
-
2013
- 2013-03-13 CN CN201380020750.9A patent/CN104302664B/zh active Active
- 2013-03-13 MY MYPI2018703207A patent/MY198567A/en unknown
- 2013-03-13 BR BR112014022692A patent/BR112014022692A8/pt not_active Application Discontinuation
- 2013-03-13 ES ES13712987.0T patent/ES2687974T3/es active Active
- 2013-03-13 PL PL13712987T patent/PL2825553T3/pl unknown
- 2013-03-13 KR KR1020207017530A patent/KR102283200B1/ko active Active
- 2013-03-13 MY MYPI2014002545A patent/MY171761A/en unknown
- 2013-03-13 DK DK13712987.0T patent/DK2825553T3/en active
- 2013-03-13 JP JP2015500534A patent/JP6883944B2/ja active Active
- 2013-03-13 KR KR20147027652A patent/KR20140135233A/ko not_active Ceased
- 2013-03-13 WO PCT/US2013/030636 patent/WO2013138400A1/en not_active Ceased
- 2013-03-13 EP EP18172145.7A patent/EP3421488A3/en not_active Withdrawn
- 2013-03-13 EP EP13712987.0A patent/EP2825553B1/en active Active
- 2013-03-13 SG SG11201405468QA patent/SG11201405468QA/en unknown
- 2013-03-13 KR KR1020217023450A patent/KR102494534B1/ko active Active
- 2013-03-13 CN CN202111438717.0A patent/CN114133454A/zh active Pending
- 2013-03-13 NZ NZ631565A patent/NZ631565A/en unknown
- 2013-03-13 MX MX2014011052A patent/MX361875B/es active IP Right Grant
- 2013-03-13 AU AU2013232266A patent/AU2013232266A1/en not_active Abandoned
- 2013-03-13 SG SG10201709018QA patent/SG10201709018QA/en unknown
- 2013-03-13 EA EA201491686A patent/EA036225B1/ru not_active IP Right Cessation
- 2013-03-13 US US13/798,205 patent/US20130243775A1/en not_active Abandoned
- 2013-03-13 SG SG10201704846VA patent/SG10201704846VA/en unknown
- 2013-03-13 CA CA2867265A patent/CA2867265C/en active Active
-
2014
- 2014-09-04 IL IL23446014A patent/IL234460B/en active IP Right Grant
- 2014-09-11 ZA ZA2014/06671A patent/ZA201406671B/en unknown
- 2014-09-12 MX MX2022012083A patent/MX2022012083A/es unknown
- 2014-09-12 MX MX2018010776A patent/MX2018010776A/es unknown
-
2017
- 2017-10-27 AU AU2017251854A patent/AU2017251854B2/en active Active
-
2018
- 2018-04-03 JP JP2018071539A patent/JP2018168152A/ja not_active Withdrawn
-
2019
- 2019-02-01 JP JP2019016596A patent/JP7308041B2/ja active Active
- 2019-04-25 US US16/394,849 patent/US11578135B2/en active Active
-
2022
- 2022-01-24 JP JP2022008369A patent/JP7579291B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511962A5 (cg-RX-API-DMAC7.html) | ||
| JP2014531409A5 (cg-RX-API-DMAC7.html) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| JP2017535257A5 (cg-RX-API-DMAC7.html) | ||
| IL253462B (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| MX2009010120A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. | |
| JP2016500251A5 (cg-RX-API-DMAC7.html) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2019523651A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2017504577A5 (cg-RX-API-DMAC7.html) | ||
| WO2005110474A3 (en) | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| JP2015501291A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509582A5 (cg-RX-API-DMAC7.html) | ||
| RU2014120694A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К iNKT | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| JP2015503909A5 (cg-RX-API-DMAC7.html) | ||
| JP2014512812A5 (cg-RX-API-DMAC7.html) | ||
| JP2015535691A5 (cg-RX-API-DMAC7.html) | ||
| JP2013542914A5 (cg-RX-API-DMAC7.html) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2016509585A5 (cg-RX-API-DMAC7.html) | ||
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc |